LLY vs REPL · P/E 39, rev $65.18B vs $825.7M cap
Eli Lilly and Company (LLY) versus Replimune Group Inc (REPL) — a side-by-side from cached financials, not a winner call.
Eli Lilly and Company (LLY) is a drug manufacturers - general company listed on NYSE. It is led by David Ricks.
Replimune Group Inc (REPL) is a biotechnology company listed on NASDAQ.
Latest reported LLY revenue for 2025-12-31 was $65.18B. Net income was $20.64B. Revenue was up 44.7% from 2024-12-31 to 2025-12-31. LLY currently screens at market cap $991.62B and trailing P/E 39.5.
REPL does not have a complete income-statement cache yet.
LLY currently screens at market cap $991.62B and trailing P/E 39.5. REPL currently screens at market cap $825.7M.
Not investment advice. Open the LLY and REPL stock pages for the full models.
Not investment advice.